Roivant and Poxel announce strategic agreement for development and commercialization of imeglimin in the U.S., Europe, and additional countries worldwide. Roivant Sciences, a global healthcare company focused on biomedical research, and Poxel SA, a biopharmaceutical company focused on the development of treatments for metabolic disorders, including type 2 diabetes, have signed a strategic development and license agreement for…
